Incidence and Risk of Peripheral Neuropathy Caused by Intravenous and Subcutaneous Injection of Bortezomib.
10.19746/j.cnki.issn.1009-2137.2019.05.046
- Author:
Zhi-Qiang LIU
1
;
Hai-Long XIA
2
;
Cheng-Jun LI
1
;
Lei XIA
3
Author Information
1. Department of Hematology, Chaohu Hospital Affiliated to Anhui Medical University，Chaohu 238000, Anhui Province, China.
2. Department of Hematology, Chaohu Hospital Affiliated to Anhui Medical University，Chaohu 238000, Anhui Province, China,Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China,E-mail: xhl1999cn@163.com.
3. Department of Psychiatry, Anhui Psychiatric Center, Anhui Medical University, Hefei 230022, Anhui Province, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
Bortezomib;
adverse effects;
Humans;
Incidence;
Injections, Subcutaneous;
Multiple Myeloma;
Peripheral Nervous System Diseases;
chemically induced
- From:
Journal of Experimental Hematology
2019;27(5):1654-1663
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare the effects of intravenous and subcutaneous injection of bortezomib on incidence and relative risk of peripheral neuropathy in patients with multiple myeloma(MM).
METHODS:The electronic database of PubMed, Embase, Cochrance library, CNKI and related meeting records were searched by computers. The data were derived all from a matched randomized controlled studies. The incidence, relative risk(RR) and 95% confidence interval of peripheral neuropathy caused by intravenous and subcustaneous injections were calculated by the statistical methods.
RESULTS:Four RCT studies were selected for meta-analysis, with a total of 911 patients (479 cases and 432 cases in the subcutaneous injection and intravenous injection groups, respectively). The incidence of peripheral neuropathy in the intravenous injection group was 41.4% (95% CI=0.137-0.692, P=0.003), and the incidence of >2 grade of peripheral neuropathy was 15.6% (95% CI=0.005-0.308, P=0.043). The corresponding incidence rates of the subcutaneous injection group were 16% (95% CI=0.021-0.299, P=0.024) and 3.4% (95% CI=-0.011-0.080, P=0.141) respectively. Compared with the intravenous injection group, the RR of peripheral neuropathy and the relative risk of peripheral neuropathy above grade 2 were 0.525, 95% CI=0.297-0.928 (P=0.027) and 0.376, 95% CI=0.196-0.722 (P=0.003) respectively.
CONCLUSION:Subcutaneous injection of bortezomib at therapeutic doses significantly reduces the incidence of peripheral neuropathy compared with intravenous injection.
